XASECANF
Market cap16mUSD
Dec 24, Last price
1.43USD
1D
-2.05%
1Q
-29.56%
Jan 2017
-99.60%
IPO
-99.84%
Name
Can Fite Biopharma Ltd
Chart & Performance
Profile
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 743 -8.27% | 810 -5.04% | 853 11.80% | |||||||
Cost of revenue | 8,938 | 10,906 | 13,695 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (8,195) | (10,096) | (12,842) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 63 | (20) | ||||||||
Tax Rate | ||||||||||
NOPAT | (8,195) | (10,159) | (12,822) | |||||||
Net income | (7,634) -25.42% | (10,236) -18.73% | (12,595) -14.93% | |||||||
Dividends | (2,590) | (715) | ||||||||
Dividend yield | 1,133.93% | 263.83% | ||||||||
Proceeds from repurchase of equity | 9,144 | 20,457 | ||||||||
BB yield | -8,253.53% | -7,548.46% | ||||||||
Debt | ||||||||||
Debt current | 27 | 48 | 53 | |||||||
Long-term debt | 53 | 76 | 195 | |||||||
Deferred revenue | 1,713 | 2,295 | 3,070 | |||||||
Other long-term liabilities | 2,295 | 3,070 | ||||||||
Net debt | (8,842) | (7,855) | (18,891) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (8,440) | (10,801) | (9,858) | |||||||
CAPEX | (2) | (9) | (11) | |||||||
Cash from investing activities | 498 | 9,502 | (14,511) | |||||||
Cash from financing activities | 9,144 | 20,457 | 20,457 | |||||||
FCF | (8,150) | (10,100) | (12,884) | |||||||
Balance | ||||||||||
Cash | 8,922 | 7,979 | 19,139 | |||||||
Long term investments | ||||||||||
Excess cash | 8,885 | 7,938 | 19,096 | |||||||
Stockholders' equity | (157,354) | (149,720) | (78,893) | |||||||
Invested Capital | 165,350 | 158,844 | 99,539 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 4,261 | 2,719 | 1,844 | |||||||
Price | 0.03 -69.05% | 0.08 -42.86% | 0.15 -26.13% | |||||||
Market cap | 111 -51.50% | 228 -15.72% | 271 13.99% | |||||||
EV | (8,731) | (7,627) | (18,620) | |||||||
EBITDA | (8,180) | (10,082) | (12,828) | |||||||
EV/EBITDA | 1.07 | 0.76 | 1.45 | |||||||
Interest | 14 | 63 | 22 | |||||||
Interest/NOPBT |